3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
7
Terminated
4
Withdrawn
2
No longer available
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
1
CNS
1
Conditions
Recurrence
2
Multiple Myeloma
2
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Glioma
1
Glioblastoma
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Dexamethasone
14
Rituximab
6
Cytarabine
5
venetoclax
4
Lenalidomide
4
Bortezomib
4
Bendamustine Hydrochloride
4
selinexor
3
pomalidomide
3
pembrolizumab
3
ibrutinib
3
fludarabine
3
carfilzomib
3
Paclitaxel
3
Gemcitabine
3
Drug Therapy
3
Cyclophosphamide
3
Calcium Dobesilate
3
ixazomib
2
gilteritinib
2
fludarabine phosphate
2
elotuzumab
2
daratumumab
2
belinostat
2
Tablets
2
Surveys and Questionnaires
2
Panobinostat
2
Oxaliplatin
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Recurrence
×
Panobinostat
×
Clear all
NCT02756663
2016-11-08
PANORAMA-5
Novartis
Phase 2
Withdrawn
NCT01115036
2013-06-19
CLBH589C
Duke University
Phase 2
Withdrawn